Protein tyrosine phosphatases: emerging role in cancer therapy resistance
Cancer Communications · 2024-06 · 44 (6) · 637-653
DOI: 10.1002/cac2.12548 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Communications, online erschienen am 13.05.2024. Verfasst von Min Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, Department of Biotherapy, Cancer Center and State Key Laboratory o…. Hauptthemen laut MEDLINE: Neoplasms, Drug Resistance, Neoplasm, Protein Tyrosine Phosphatases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Sichuan Province, 135 Project for Disciplines of Excellence-Clinical Research Incubation Project.
Abstract (Originalsprache)
Background Tyrosine phosphorylation of intracellular proteins is a post‐translational modification that plays a regulatory role in signal transduction during cellular events. Dephosphorylation of signal transduction proteins caused by protein tyrosine phosphatases (PTPs) contributed their role as a convergent node to mediate cross‐talk between signaling pathways. In the context of cancer, PTP‐mediated pathways have been identified as signaling hubs that enabled cancer cells to mitigate stress induced by clinical therapy. This is achieved by the promotion of constitutive activation of growth‐stimulatory signaling pathways or modulation of the immune‐suppressive tumor microenvironment. Preclinical evidences suggested that anticancer drugs will release their greatest therapeutic potency when combined with PTP inhibitors, reversing drug resistance that was responsible for clinical failures during cancer therapy. Areas covered This review aimed to elaborate recent insights that supported the involvement of PTP‐mediated pathways in the development of resistance to targeted therapy and immune‐checkpoint therapy. Expert opinion This review proposed the notion of PTP inhibition in anticancer combination therapy as a potential strategy in clinic to achieve long‐term tumor regression. Ongoing clinical trials are currently underway to assess the safety and efficacy of combination therapy in advanced‐stage tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West C…
- West China Biomedical Big Data Center, Med-X Center for Informatics, Sichuan University, Chengdu, Sichuan, P. R. China.
- Emergency Department, Zigong Fourth People's Hospital, Chengdu, Sichuan, P. R. China.
ORCID-Profile: Guan Wang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Sichuan Province
- 135 Project for Disciplines of Excellence-Clinical Research Incubation Project
- West China Hospital
- West China Nursing Discipline Development Special Fund Project
- Sichuan University
- West China Hospital, Sichuan University
Zitieren
APA
Zhao, M., Shuai, W., Su, Z., Xu, P., Wang, A., Sun, Q., & Wang, G. (2024). Protein tyrosine phosphatases: emerging role in cancer therapy resistance. Cancer Communications, 44(6), 637-653. https://doi.org/10.1002/cac2.12548
Vancouver
Zhao M, Shuai W, Su Z, Xu P, Wang A, Sun Q, et al. Protein tyrosine phosphatases: emerging role in cancer therapy resistance. Cancer Communications. 2024;44(6):637-653. doi:10.1002/cac2.12548
BibTeX
@article{Zhao2024,
author = {Zhao, Min and Shuai, Wen and Su, Zehao and Xu, Ping and Wang, Aoxue and Sun, Qiu and Wang, Guan},
title = {Protein tyrosine phosphatases: emerging role in cancer therapy resistance},
journal = {Cancer Communications},
year = {2024},
volume = {44},
number = {6},
pages = {637--653},
doi = {10.1002/cac2.12548}
}
EUVIMED